Immunitybio SEC Filings

Type
Report
Date
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben1/26/2026
4Insidertransaktion1/21/2026
4Insidertransaktion1/21/2026
144144-Formular1/20/2026
144144-Formular1/20/2026
144144-Formular1/16/2026
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben1/15/2026
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben1/14/2026
4Insidertransaktion1/5/2026
4Insidertransaktion1/5/2026
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben12/29/2025
424B5424B5-Formular12/29/2025
33-Formular12/16/2025
4Insidertransaktion12/16/2025
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben12/15/2025
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben12/12/2025
SCHEDULE 13D/ASCHEDULE 13D/A-Formular11/10/2025
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben11/5/2025
10-QQuartalsbericht11/5/2025
DEF 14CDEF 14C-Formular10/20/2025
PRE 14CPRE 14C-Formular10/8/2025
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben8/8/2025
10-QQuartalsbericht8/5/2025
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben8/5/2025
424B5424B5-Formular7/28/2025
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben7/25/2025
S-8S-8-Formular6/23/2025
4Insidertransaktion6/20/2025
4Insidertransaktion6/20/2025
4Insidertransaktion6/20/2025
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben6/20/2025
4Insidertransaktion6/20/2025
4Insidertransaktion6/20/2025
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben5/12/2025
10-QQuartalsbericht5/12/2025
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben5/5/2025
DEF 14ADEF 14A-Formular4/30/2025
DEFA14ADEFA14A-Formular4/30/2025
ARSARS-Formular4/30/2025
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben4/15/2025
424B5424B5-Formular4/8/2025
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben4/8/2025
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben3/19/2025
10-KJahresbericht3/3/2025
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben3/3/2025
4Insidertransaktion2/25/2025
4Insidertransaktion2/25/2025
4Insidertransaktion2/25/2025
4Insidertransaktion2/25/2025
4Insidertransaktion2/25/2025
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben2/13/2025
4Insidertransaktion2/12/2025
4Insidertransaktion2/12/2025
4Insidertransaktion2/12/2025
4Insidertransaktion2/12/2025
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben2/7/2025
4Insidertransaktion1/24/2025
4Insidertransaktion1/3/2025
4Insidertransaktion1/3/2025
4Insidertransaktion12/16/2024
4Insidertransaktion12/12/2024
424B5424B5-Formular12/12/2024
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben12/11/2024
424B5424B5-Formular12/10/2024
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben12/10/2024
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben11/19/2024
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben11/12/2024
10-QQuartalsbericht11/12/2024
10-QQuartalsbericht8/12/2024
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben7/18/2024
S-8S-8-Formular6/20/2024
4Insidertransaktion6/13/2024
4Insidertransaktion6/13/2024
4Insidertransaktion6/13/2024
4Insidertransaktion6/13/2024
4Insidertransaktion6/13/2024
4Insidertransaktion6/13/2024
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben6/12/2024
10-QQuartalsbericht5/9/2024
EFFECTEFFECT-Formular5/2/2024
CORRESPCORRESP-Formular4/30/2024
DEFA14ADEFA14A-Formular4/29/2024
DEF 14ADEF 14A-Formular4/29/2024
ARSARS-Formular4/29/2024
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben4/23/2024
S-3ASRS-3ASR-Formular4/17/2024
UPLOADUPLOAD-Formular4/3/2024
S-3S-3-Formular3/29/2024
10-KJahresbericht3/19/2024
4Insidertransaktion2/26/2024
4Insidertransaktion2/26/2024
4Insidertransaktion2/26/2024
4Insidertransaktion2/26/2024
8-KAllgemeines, mitteilungspflichtiges Informationsschreiben2/26/2024
4Insidertransaktion2/26/2024
4Insidertransaktion2/6/2024
4Insidertransaktion2/2/2024
4Insidertransaktion2/2/2024
4Insidertransaktion2/2/2024
SC 13D/ASC 13D/A-Formular1/4/2024

Immunitybio Documents 2026

This page contains all official documents and SEC filings for Immunitybio stock (IBRX, ISIN: US45256X1037). This includes annual reports (Form 10-K), quarterly reports (Form 10-Q), and insider transactions (Form 4). Currently 100 documents are available. Data is updated regularly to provide investors with a complete overview of Immunitybio's regulatory filings.

Immunitybio Stock analysis

Immunitybio Translate this as near as possible to English. ImmunityBio Inc is a biotechnology company specializing in innovative methods to combat cancer and other serious diseases. The company was founded in 2015 by esteemed biotech entrepreneur and scientist, Dr. Patrick Soon-Shiong. The idea behind ImmunityBio was to create a company focused on developing advanced immunotherapies that involve the human immune system in the fight against cancer. The business model is based on several business units, including research and development, diagnostics, and therapeutics. In recent years, the company has expanded through a series of significant acquisitions and mergers, including CytRx Corporation, NantWorks LLC, and NantKwest Inc. Together, these mergers have expanded and united the resources and expertise of ImmunityBio to achieve new advancements in oncology. ImmunityBio has also developed a variety of products focused on strengthening the immune system, including its leading drug, INT-001, intended for the treatment of lung, pancreatic, breast, stomach, and colorectal cancer. The company has also developed diagnostic products, such as the ImmuneMap™ test, which analyzes the patient's immune profile and can contribute to better combinations of existing immunotherapies. Another business unit is the service department, which focuses on providing services related to precision medicine. ImmunityBio offers a wide range of personalized drugs and services to help provide patients with better and more effective treatment. The company also has an extensive pipeline of immunotherapies for various indications, including several clinical trials for the treatment of lung cancer, pancreatic cancer, and breast cancer. The portfolio includes both single agents and combination therapies, which the company will introduce after a rigorous phase 1 study. Overall, ImmunityBio has an ambitious goal of being a leading player in the innovation of immunotherapies. Through a multidisciplinary approach to the discovery and development of new treatments, ImmunityBio is working to defeat cancer by strengthening the immune system and improving the quality of life for patients worldwide.